Its lead product candidate, HXP124 carried out in a topical components, is a possible new prescription remedy for toenail fungal infections (or onychomycosis). Hexima is these days accomplishing a 132 affected person Australian section IIb medical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protective HXP124 in primary markets globally.
Hexima is primarily based in Melbourne, Australia.
It’s expected that HXL will listing at the ASX throughout December 2020.
Hexima Restricted is a biotechnology corporate actively engaged within the analysis and construction of plant-derived molecules to be used in human well being and agriculture.